首页> 外文期刊>JAMA: the Journal of the American Medical Association >The new antiepileptic drugs: scientific review.
【24h】

The new antiepileptic drugs: scientific review.

机译:新型抗癫痫药:科学综述。

获取原文
获取原文并翻译 | 示例
       

摘要

CONTEXT: The past decade has brought many advances to the treatment of epilepsy, including many new pharmacological agents. Primary care physicians often care for patients with epilepsy and therefore should be familiar with the new options available. OBJECTIVE: To review data regarding the efficacy and tolerability of antiepileptic drugs introduced in the past decade. DATA SOURCES: A search of the Cochrane Central Register of Controlled Trials was performed to identify all published human and English-language randomized controlled trials evaluating the efficacy and tolerability of the antiepileptic drugs that have been approved for use in the United States since 1990. Additional reports evaluating pharmacokinetic properties were identified through a MEDLINE search as well as review of article bibliographies. STUDY SELECTION AND DATA EXTRACTION: Search terms included felbamate, gabapentin, lamotrigine, topiramate, tiagabine, levetiracetam, oxcarbazepine, and zonisamide. Studies were selected if efficacy and tolerability were reported as major outcome measures. Included studies (n = 55) enrolled a minimum of 20 adult subjects and had a treatment period of at least 6 weeks. DATA SYNTHESIS: Eight new antiepileptic drugs have been approved for use in the United States in the past decade. Each new antiepileptic drug is well tolerated and demonstrates statistically significant reductions in seizure frequency over baseline. No randomized controlled trials have compared the new antiepileptic drugs with each other or against the traditional antiepileptic drugs. Although there is no evidence to suggest that the newer medications are more efficacious, several studies have demonstrated broader spectrum of activity, fewer drug interactions, and overall better tolerability of the new agents. CONCLUSIONS: New antiepileptic drugs offer many options in the treatment of epilepsy, each with unique mechanisms of action as well as adverse effect profiles. The new antiepileptic drugs are well tolerated with few adverse effects, minimal drug interactions, and a broad spectrum of activity.
机译:上下文:过去的十年为癫痫的治疗带来了许多进步,包括许多新的药理学作用。初级保健医生经常照顾癫痫患者,因此应熟悉可用的新选择。目的:回顾过去十年中引入的抗癫痫药的功效和耐受性的数据。数据来源:进行了Cochrane对照试验中央登记册的检索,以鉴定所有已评估的抗癫痫药的功效和耐受性的已发表的人类和英语随机对照试验,这些试验已于1990年在美国获准使用。通过MEDLINE搜索以及文章书目审查,鉴定了评价药代动力学性质的报告。研究选择和数据提取:检索词包括非尔贝特,加巴喷丁,拉莫三嗪,托吡酯,替加滨,左乙拉西坦,奥卡西平和唑尼沙胺。如果功效和耐受性被报告为主要结局指标,则选择研究。纳入的研究(n = 55)至少招募了20名成人受试者,并且治疗时间至少为6周。数据合成:在过去的十年中,八种新的抗癫痫药被批准在美国使用。每种新的抗癫痫药均具有良好的耐受性,并且与基线相比,癫痫发作频率具有统计学上的显着降低。没有随机对照试验将新的抗癫痫药彼此之间或与传统的抗癫痫药进行比较。尽管没有证据表明新药更有效,但一些研究表明,新药的活性范围更广,药物相互作用更少,总体耐受性更高。结论:新的抗癫痫药为癫痫的治疗提供了许多选择,每种选择都有独特的作用机制以及不良反应。新的抗癫痫药具有良好的耐受性,几乎没有副作用,药物相互作用最小,且活性范围广。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号